BioInvent remains focused on BI-1206, its lead FcγRIIB‑blocking antibody, and BI-1808, its anti-TNFR2 antibody,and the BI‑1607 program is currently paused BioInvent International AB ("BioInvent") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback